Vitae Pharmaceuticals, Inc.

Novartis Ag

Boehringer Ingelheim International Gmbh

Merck Sharp + Dohme Corp.

Ifm Due, Inc.

Novartis Inflammasome Research, Inc.

Shankar Venkatraman

Yajun Zheng

Suresh B Singh

Jing Yuan

Salvacion Cacatian

Lanqi Jia

Angel Morales-Ramos

Lawrence Wayne Dillard

Zhenrong Xu

William R Roush

Hans Martin Seidel

David A Claremon

Jason David Katz

Dong-Ming Shen

Shomir Ghosh

Klaus Fuchs

Gary D Glick

Katerina Leftheris

Linghang Zhuang

David Guenther Winkler

Yi Fan

Stephen D Lotesta

Chengguo Dong

Luigi Franchi

Guosheng Wu

Anthony William Opipari, Jr

Niklas Heine

Cornelia Dorner-Ciossek

Yi Zhao

Yuri Bukhtiyarov

Deepak S Lala

Stephan D Parent

Travis Lee Houston

Andrew Marcus

Jonathan Timothy Reeves

Georg Rast

Brian McKeever

Zhongren Wu

Benito Munoz

John S Wai

Peter D Williams

Bowei Wang

Wayne J Thompson

Alec D Lebsack

Dai-Shi Su

Mark W Embrey

Peter Emmanuel Maligres

Achim Sauer

Zhiguo Jake Song

Weichao George Chen

Thorsten E Fisher

Tao Pei

Jingjun Yin

David C Dubost

Michael Shevlin

Neil A Strotman

Richard C A Isaacs

Matthew L Maddess

Dietrich P Steinhuebel

Ulrike Gross

Richard G Ball

Eric J Choi

Sarah L Trice

Neil Campbell

Jonathan Reeves

Brian Mckeever

Anthony William Opipari Jr

Anthony William Opipari

Matthew Maddess

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Compounds and compositions for treating conditions associated with NLRP activity

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Inhibitors of the menin-MLL interaction

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) having formula (I) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Compounds and compositions for treating conditions associated with STING activity

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

Sulphonamides and compositions thereof for treating conditions associated with NLRP activity

This disclosure features chemical entities of formula I (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same. 

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging. 

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: 

Growing community of inventors

Lansdale, PA, United States of America

Shankar Venkatraman